These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 35450946)
1. FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps. Rizk JG; Lewin JC BMJ Evid Based Med; 2023 Apr; 28(2):78-82. PubMed ID: 35450946 [TBL] [Abstract][Full Text] [Related]
2. Ignoring the Experts: Implications of the FDA's Aduhelm Approval. Maulden A Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585 [TBL] [Abstract][Full Text] [Related]
3. Can we learn lessons from the FDA's approval of aducanumab? Liu KY; Howard R Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787 [TBL] [Abstract][Full Text] [Related]
4. Accelerated Approval of Aducanumab: Where Do We Stand Now? Barenholtz Levy H Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939 [TBL] [Abstract][Full Text] [Related]
5. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. Herder M J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277 [TBL] [Abstract][Full Text] [Related]
6. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. Zhang AD; Schwartz JL; Ross JS Milbank Q; 2019 Sep; 97(3):796-819. PubMed ID: 31304643 [TBL] [Abstract][Full Text] [Related]
7. Aducanumab for Alzheimer's disease: A regulatory perspective. Nisticò R; Borg JJ Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830 [TBL] [Abstract][Full Text] [Related]
8. Controversial Approval of New Drug to Treat Alzheimer's Disease. Aschenbrenner DS Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982 [TBL] [Abstract][Full Text] [Related]
9. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease. Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658 [TBL] [Abstract][Full Text] [Related]
10. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Vaz M; Silva V; Monteiro C; Silvestre S Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326 [TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013-2018. Janiaud P; Irony T; Russek-Cohen E; Goodman SN Ann Intern Med; 2021 Nov; 174(11):1603-1611. PubMed ID: 34543584 [TBL] [Abstract][Full Text] [Related]
13. Making the Case for Accelerated Withdrawal of Aducanumab. Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287 [TBL] [Abstract][Full Text] [Related]
14. Revisiting FDA Approval of Aducanumab. Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282 [No Abstract] [Full Text] [Related]
15. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021. Daval CJR; Teng TW; Russo M; Kesselheim AS JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270 [TBL] [Abstract][Full Text] [Related]
16. An insider's perspective on FDA approval of aducanumab. Wang Y Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506 [TBL] [Abstract][Full Text] [Related]
17. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies. Yuksel JM; Noviasky J; Britton S Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846 [No Abstract] [Full Text] [Related]
18. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. DiStefano MJ; Alexander GC; Polsky D; Anderson GF J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210 [TBL] [Abstract][Full Text] [Related]
19. The FDA Oncology Center of Excellence and precision medicine. Goldberg KB; Blumenthal GM; McKee AE; Pazdur R Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511 [TBL] [Abstract][Full Text] [Related]
20. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Nguyen NT; Cook DM; Bero LA Clin Ther; 2006 Aug; 28(8):1231-1243. PubMed ID: 16982301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]